| Padagis US LLC |
00574093125 |
Doxorubicin Hydrochloride Liposome Injection 50 mg/25 mL (2mg/mL) 25mL |
2021-10-25 |
1515.6000 |
Product is be priced to deliver value to the market as compared to the Brand referenced drug. |
None |
39976 |
None |
None |
None |
None |
None |
None |
As a generic manufacturer, Padagis does not have information available to accurately determinate the number of patients that could potentially have a condition for which the drug may be prescribed. Padagis neither collects nor uses estimated patient information and does not believe there is publicly available data that accurately represents the number of patients for all indications.
Based on NSP data available to Padagis, Padagis estimates that approximately 39,976 Total Units were sold for this drug in the past 12 months, but number of units sold should not be misinterpreted as an accurate estimate of the number of patients with a condition for which the new drug may be prescribed, as dosage and therapy may vary across individual patients. |
None |
| Par Pharmaceutical |
00254205301 |
Chlorzoxazone Tablets 375mg 100s |
2021-06-10 |
370.0000 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available, as of the date of this submission. As a result, Par has left the marketing and pricing plan description data field blank.
(2) Par did not conduct any epidemiologic studies or analyses on the incidence and prevalence of the conditions, at the patient level, treated by this product. Par notes that this product is indicated adjunct to other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The World Health Organization (“WHO”) indicates approximately 1,710,000,000 people have musculoskeletal conditions world-wide (see https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions#:~:text=%20Musculoskeletal%20conditions%20include%20conditions%20that%20affect%3A%20,body%20areas%20or%20systems%2C%20such%20as...%20More%20 ).
However, WHO does not specify the number of patients diagnosed each month or year with musculoskeletal conditions. Further, Par does not know, and does not have access to, the prescribing patterns of healthcare practitioners at the patient level.
Par is therefore unable to provide any additional detail regarding the Estimated Number of Patients who may be prescribed Par’s Chlorzoxazone Tablets because the information is not in the public domain. Thus, we understand our initial filings to be consistent with the statute, Cal. Health & Safety Code § 127681(c), which allows a manufacturer to “limit the information reported pursuant to subdivision (b) to that which is otherwise in the public domain or publicly available.” Subdivision (b) of the same requires the number of estimated patients to be included in new drug reports. This limitation is further noted on the OSHPD’s webpage titled “Prescription Drugs Introduced to Market” that contains the most recent published new drug reports. This webpage states: “Manufacturers may withhold information that is not in the public domain.” See Prescription Drugs Introduced to Market, available at: https://data.chhs.ca.gov/dataset/prescription-drugs-introduced-to-market.
Accordingly, for the foregoing reasons, Par has left the “estimated number of patients” data field blank.
(3) Par did not acquire this product. As a result, Par has left the acquisition related data fields blank. |
None |
| Par Pharmaceutical |
49884015576 |
Varenicline Tablets .5mg 56s |
2021-09-16 |
364.5200 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available, as of the date of this submission. As a result, Par has left the marketing and pricing plan description data field blank.
(2) Par did not conduct any epidemiologic studies or analyses on the incidence and prevalence of the conditions, at the patient level, treated by this product. Par notes that this product is indicated as an aid to smoking cessation treatment. The Centers for Disease Control and Prevention (“CDC”) indicates that in 2015 22.7 million adult smokers in the United States wanted to quit smoking. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation/smoking-cessation-fast-facts/index.html
However, CDC does not specify the number of smokers intending to quit each month or year. Further, Par does not know, and does not have access to, the prescribing patterns of healthcare practitioners at the patient level.
Par is therefore unable to provide any additional detail regarding the Estimated Number of Patients who may be prescribed Par’s Varenicline Tablets because the information is not in the public domain. Thus, we understand our initial filings to be consistent with the statute, Cal. Health & Safety Code § 127681(c), which allows a manufacturer to “limit the information reported pursuant to subdivision (b) to that which is otherwise in the public domain or publicly available.” Subdivision (b) of the same requires the number of estimated patients to be included in new drug reports. This limitation is further noted on the OSHPD’s webpage titled “Prescription Drugs Introduced to Market” that contains the most recent published new drug reports. This webpage states: “Manufacturers may withhold information that is not in the public domain.” See Prescription Drugs Introduced to Market, available at: https://data.chhs.ca.gov/dataset/prescription-drugs-introduced-to-market.
Accordingly, for the foregoing reasons, Par has left the “estimated number of patients” data field blank.
(3) Par did not acquire this product. As a result, Par has left the acquisition related data fields blank. |
None |
| Par Pharmaceutical |
49884055601 |
Isosorbide Dinitrate Tablets, USP 40mg 100s |
2021-12-13 |
1335.3700 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available, as of the date of this submission. As a result, Par has left the marketing and pricing plan description data field blank.
(2) Par did not conduct any epidemiologic studies or analyses on the incidence and prevalence of the conditions, at the patient level, treated by this product. Moreover, Par notes that because this product is a generic, Par did not consider, nor did it identify, the estimated patient population in determining market need for the product.
Accordingly, Par is unable to provide an estimate of the average number of patients who may be treated by this product beyond publicly available data.
Par notes that this product is indicated for the prevention of angina pectoris due to coronary artery disease. The Centers for Disease Control and Prevention (“CDC”) estimates that 18.2 million adults in the United States have coronary artery disease and the Mayo Clinic notes that angina is a common symptom of coronary artery disease. ( https://www.cdc.gov/heartdisease/facts.htm, https://www.mayoclinic.org/diseases-conditions/angina/symptoms-causes/syc-20369373 )
The CDC did not indicate how many cases of coronary artery disease occur each month.
Par is therefore unable to provide any additional detail regarding the Estimated Number of Patients who may be prescribed Par’s Isosorbide because the information is not in the public domain. Thus, we understand our initial filings to be consistent with the statute, Cal. Health & Safety Code § 127681(c), which allows a manufacturer to “limit the information reported pursuant to subdivision (b) to that which is otherwise in the public domain or publicly available.” Subdivision (b) of the same requires the number of estimated patients to be included in new drug reports. This limitation is further noted on the OSHPD’s webpage titled “Prescription Drugs Introduced to Market” that contains the most recent published new drug reports. This webpage states:
“Manufacturers may withhold information that is not in the public domain.” See Prescription Drugs Introduced to Market, available at:
https://data.chhs.ca.gov/dataset/prescription-drugs-introduced-to-market.
Accordingly, for the foregoing reasons, Par has left the “estimated number of patients” data field blank.
(3) Par did not acquire this product. As a result, Par has left the acquisition related data fields blank. |
None |
| Pfizer |
00069102902 |
XELJANZ 1MG/ML ORSOL 1X240ML PBTL US |
2021-02-08 |
3944.3900 |
None |
1 |
3000 |
None |
None |
None |
None |
None |
None |
Comment regarding Field 5 - Pfizer does not believe the Marketing/Pricing Plan information is publicly available and has not released this information in the public domain. Accordingly, Pfizer is limiting its response to this item pursuant to Cal. Health & Safety Code § 127681(c). Comment regarding Field 7 - Pfizer estimates that in total, approximately 3,000 patients across the United States, could potentially receive the Oral Solution formulation. Comment regarding Fields 10-13: Xeljanz Oral Solution was not acquired; therefore, Columns 10 – 13 are intentionally left blank. |
None |
| Pfizer |
00409012001 |
Daptomycin for Injection 350mg per Vial (1’s) |
2021-10-04 |
50.0000 |
None |
1 |
393466 |
None |
None |
None |
None |
None |
None |
Comment regarding Field 5 - Pfizer does not believe the Marketing/Pricing Plan information is publicly available and has not released this information in the public domain. Accordingly, Pfizer is limiting its response to this item pursuant to Cal. Health & Safety Code § 127681(c). Comment regarding Field 7 - Approximately 393,466 patients are estimated to receive Daptomycin annually. Comment regarding Fields 10-13: Daptomycin was not acquired; therefore, Columns 10 – 13 are intentionally left blank. |
None |
| Pfizer |
00409012201 |
Daptomycin for Injection 500mg per Vial (1’s) |
2021-10-04 |
79.0000 |
None |
1 |
393466 |
None |
None |
None |
None |
None |
None |
Comment regarding Field 5 - Pfizer does not believe the Marketing/Pricing Plan information is publicly available and has not released this information in the public domain. Accordingly, Pfizer is limiting its response to this item pursuant to Cal. Health & Safety Code § 127681(c). Comment regarding Field 7 - Approximately 393,466 patients are estimated to receive Daptomycin annually. Comment regarding Fields 10-13: Daptomycin was not acquired; therefore, Columns 10 – 13 are intentionally left blank. |
None |
| PharmaEssentia USA Corporation |
73536050001 |
BESREMi (Ropeginterferon alfa-2b-njft) 500 mcg/ml single use vial |
2021-12-03 |
6988.0000 |
None |
1 |
161110 |
None |
1 |
None |
None |
None |
None |
None |
None |
| Piramal Critical Care |
66794023444 |
Dexmedetomidine Hydrochloride Injection, USP 200 mcg/50mL (4 mcg/mL) |
2021-08-15 |
720.0000 |
Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Piramal Critical Care’s Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is priced responsibly and in line with current market conditions. |
None |
750315 |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Piramal is limiting its response to that which is otherwise in the public domain or publicly available. The Estimated Patient amount is based on the number of eaches sold in the last 12 month period from July 2020 through June 2021. This number does not account for multiple vials dosed to a single patient as this information is not readily available. This product was not acquired; however, Piramal's marketing rights were in-licensed. Piramal does not believe this information is publicly available and has not released this information in the public domain. |
None |
| Piramal Critical Care |
66794023541 |
Dexmedetomidine Hydrochloride Injection, USP 400 mcg/100mL (4 mcg/mL) |
2021-08-15 |
720.0000 |
Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Piramal Critical Care’s Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is priced responsibly and in line with current market conditions. |
None |
3237152 |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Piramal is limiting its response to that which is otherwise in the public domain or publicly available. The Estimated Patient amount is based on the number of eaches sold in the last 12 month period from July 2020 through June 2021. This number does not account for multiple vials dosed to a single patient as this information is not readily available. This product was not acquired; however, Piramal's marketing rights were in-licensed. Piramal does not believe this information is publicly available and has not released this information in the public domain. |
None |
| Primus Pharmaceuticals Inc |
68040071428 |
Sernivo® Spray; Betamethasone dipropionate 0.05% |
2021-08-02 |
997.5000 |
None |
1 |
45000 |
None |
None |
2021-03-11 |
None |
1 |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=554, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=555 |
| Progenics Pharmaceuticals, Inc. |
71258002200 |
PYLARIFY® (piflufolastat F 18) Injection |
2021-05-26 |
4600.0000 |
Product will be marketed in the US and the pricing model will be consistant with our WAC Pricing through December 31, 2021 |
None |
250000 |
None |
1 |
None |
None |
None |
None |
Brand New Product to Market, we do not have estimate of usage yet. |
None |
| Puma Biotechnology, Inc. |
70437024033 |
Nerlynx (neratinib) 40mg 133 count bottle |
2021-06-21 |
12940.0000 |
None |
1 |
3350 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088077200 |
Sumansetron, sumatriptan tablets USP 50mg (9ct) + Ondansetron tablets USP 4mg (30ct) |
2021-01-01 |
3352.8000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
0 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088017554 |
Probitrol, capsules, 31 billion, 30ct |
2021-01-04 |
1744.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
0 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088017457 |
Promerol, capsules, 31 billion, 30ct |
2021-01-04 |
3136.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
0 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088017354 |
Vitranol Fe, caplets, multivitamin + iron, 30ct |
2021-01-04 |
1800.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
0 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088017754 |
Venexa Fe, multivitamin + iron (30CT) |
2021-01-29 |
1930.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
150000 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088017654 |
Venexa, caplets, multivitamin, 30ct |
2021-01-29 |
1544.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
0 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088017854 |
Pretrate, prenatal/postnatal multivitamin, (30ct) caplets |
2021-02-01 |
1460.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
2000000 |
None |
None |
None |
None |
None |
None |
0 |
None |
| PureTek Corporation |
59088017954 |
Lacterol (30ct), probiotic (30ct) |
2021-02-10 |
1962.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
100000 |
None |
None |
None |
None |
None |
None |
Dispensed by prescription |
None |
| PureTek Corporation |
59088018158 |
Foltin-Z, multivitamin (60ct) |
2021-02-11 |
1740.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
150000 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088018258 |
Ribotin- E, multivitamin (60ct) caplets |
2021-02-11 |
1740.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
150000 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088018058 |
Zintrexyl-C, multivitamin (60ct) |
2021-02-11 |
1740.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
150000 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088018354 |
Probitran, probiotic (30ct) |
2021-05-03 |
1962.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
100000 |
None |
None |
None |
None |
None |
None |
dispensed by prescription |
None |
| PureTek Corporation |
59088018454 |
Purefoltin, Folic acid 1mg + Vitamin D3 5,000 IU (30ct) |
2021-05-03 |
2200.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
300000 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088018654 |
Ventrixyl, multivitamin (30ct) |
2021-06-04 |
1800.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
150000 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088046607 |
Lidogel, Lidocaine HCI 2.8% Gel, (100g) |
2021-07-21 |
1516.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
250000 |
None |
None |
None |
None |
None |
None |
0 |
None |
| PureTek Corporation |
59088018754 |
Ventrixyl Fe, Multivitamin (30ct) tablets |
2021-08-11 |
1800.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
150000 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088019454 |
Probinate, probiotic, (30ct) capsules |
2021-08-20 |
1480.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
100000 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088019354 |
Vitramyn, multivitamin (30ct) caplets |
2021-08-20 |
1800.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
150000 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088018554 |
Folditam, Folic Acid 1mg + Vit D3 10,000IU, tablets (30ct) |
2021-09-02 |
1704.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
2000000 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088043207 |
Radiaura Skin Recovery Cream, Lidocaine HCI 3%_ Hydrocotisone Acetate 0.5%, cream (85g) |
2021-09-02 |
1123.8100 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
500000 |
None |
None |
None |
None |
None |
None |
None |
None |
| PureTek Corporation |
59088048058 |
Foliflex Multivitamin, 30ct caplets |
2021-10-14 |
1392.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
350000 |
None |
None |
None |
None |
None |
None |
Dispensed by prescription only |
None |
| PureTek Corporation |
59088047507 |
Lidorex. Lidocaie HCI 2.8% Gel, 3.5oz (100g) |
2021-10-14 |
1516.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
275000 |
None |
None |
None |
None |
None |
None |
Dispensed by prescription only |
None |
| PureTek Corporation |
59088020054 |
Foltamin, Folic Acid 1mg + Vitamin D3 5000IU, tablets (30ct) |
2021-11-29 |
1760.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
300000 |
None |
None |
None |
None |
None |
None |
Dispensed by prescription only |
None |
| PureTek Corporation |
59088071500 |
Lidotor, Lidocaine 2.5%/Prilocaine 2.5% cream USP 30gm + Occlusive Dressing (5ct) |
2021-11-29 |
1820.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
150000 |
None |
None |
None |
None |
None |
None |
Dispensed by prescription only |
None |
| PureTek Corporation |
59088019954 |
Probisol, 2 Strain AcidoBifido 31 Billion, capsules (30ct) |
2021-11-29 |
1569.6000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising.
There will be no direct-to-consumer marketing such as TV ads, magazine or journal ads. This drug is marketed through the use of licensed wholesalers that distribute the products. |
None |
250000 |
None |
None |
None |
None |
None |
None |
Dispensed by prescription only |
None |